Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, September 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 145 articles:
HTML format


 

Single Articles

  1. OKABE K, Shindo T, Maehana T, Nishiyama N, et al
    Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
    Jpn J Clin Oncol. 2018 Aug 28. pii: 5085500. doi: 10.1093.
    Abstract    

    Abstract available

  2. ASHE CG, Bagnell S, Gray S
    Images - Isolated forearm soft tissue metastasis from bladder cancer.
    Can Urol Assoc J. 2018 Aug 30. pii: cuaj.5341. doi: 10.5489/cuaj.5341.
    Abstract    



  3. ZHU S, Corsetti S, Wang Q, Li C, et al
    Optical sensory arrays for the detection of urinary bladder cancer related volatile organic compounds (VOCs).
    J Biophotonics. 2018 Aug 31:e201800165. doi: 10.1002/jbio.201800165.
    Abstract    

    Abstract available

  4. WANG C, Tao W, Ni S, Chen Q, et al
    Upregulation of lncRNA snoRNA host gene 6 regulates NUAK family SnF1-like kinase-1 expression by competitively binding microRNA-125b and interacting with Snail1/2 in bladder cancer.
    J Cell Biochem. 2018 Aug 30. doi: 10.1002/jcb.27387.
    Abstract    

    Abstract available

  5. RODRIGUEZ-VIDA A, Lerner SP, Bellmunt J
    The Cancer Genome Atlas Project in Bladder Cancer.
    Cancer Treat Res. 2018;175:259-271.
    Abstract    

    Abstract available

  6. LEE DJ, Chang SS
    The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer.
    Cancer Treat Res. 2018;175:193-214.
    Abstract    

    Abstract available

  7. MITRA AP, Daneshmand S
    Molecular Prognostication in Bladder Cancer.
    Cancer Treat Res. 2018;175:165-191.
    Abstract    

    Abstract available

  8. KISS B, Marcq G, Liao JC
    Optical and Cross-Sectional Imaging Technologies for Bladder Cancer.
    Cancer Treat Res. 2018;175:139-163.
    Abstract    

    Abstract available

  9. ROUPRET M
    Immunotherapy for bladder cancer: the fight is on.
    World J Urol. 2018 Aug 30. pii: 10.1007/s00345-018-2468.
    Abstract    



  10. ISHIDA K, Hsieh MH
    Understanding Urogenital Schistosomiasis-Related Bladder Cancer: An Update.
    Front Med (Lausanne). 2018;5:223.
    Abstract    

    Abstract available

  11. TAN MP, Attard G, Huddart RA
    Circulating Tumour DNA in Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  12. FUKUHARA H, Inoue K
    [Navigation Surgery for Bladder Cancer by ALA-PDD].
    Gan To Kagaku Ryoho. 2018;45:1144-1146.
    Abstract    

    Abstract available

  13. GEELVINK M, Babmorad A, Maurer A, Stohr R, et al
    Diagnostic and Prognostic Implications of FGFR3(high)/Ki67(high) Papillary Bladder Cancers.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  14. LI B, Li Y
    [Comprehensive therapy of bladder preservation for muscle invasive bladder cancer].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018;43:82-89.
    Abstract    

    Abstract available

  15. PSUTKA SP, Porten S
    Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape.
    Eur Urol Focus. 2018 Aug 25. pii: S2405-4569(18)30227.
    Abstract    



  16. FAREED MM, DeMora L, Esnaola NF, Denlinger CS, et al
    Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas.
    J Gastrointest Oncol. 2018;9:762-768.
    Abstract    

    Abstract available

  17. WANG K, Tan SL, Lu Q, Xu R, et al
    Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer.
    Am J Chin Med. 2018 Aug 27:1-12. doi: 10.1142/S0192415X18500714.
    Abstract    

    Abstract available

  18. CHI H, Yang R, Zheng X, Zhang L, et al
    LncRNA RP11-79H23.3 Functions as a Competing Endogenous RNA to Regulate PTEN Expression through Sponging hsa-miR-107 in the Development of Bladder Cancer.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  19. LODEWIJK I, Duenas M, Rubio C, Munera-Maravilla E, et al
    Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  20. ZENG Z, Zhou W, Duan L, Zhang J, et al
    Circular RNA circ-VANGL1 as a competing endogenous RNA contributes to bladder cancer progression by regulating miR-605-3p/VANGL1 pathway.
    J Cell Physiol. 2018 Aug 26. doi: 10.1002/jcp.27162.
    Abstract    

    Abstract available

  21. ZHANG Z, Liu Y, Wang K, Zhu K, et al
    Activation of type 4 metabotropic glutamate receptor promotes cell apoptosis and inhibits proliferation in bladder cancer.
    J Cell Physiol. 2018 Aug 26. doi: 10.1002/jcp.27089.
    Abstract    

    Abstract available

  22. JUNG JH, You S, Oh JW, Yoon J, et al
    Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
    Cancer Lett. 2018 Aug 23. pii: S0304-3835(18)30526.
    Abstract    

    Abstract available

  23. RAILKAR R, Agarwal PK
    Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations.
    Eur Urol Focus. 2018 Aug 22. pii: S2405-4569(18)30224.
    Abstract    

    Abstract available

  24. HUANG GL, Luo HL, Chen YT, Cheng YT, et al
    Oncologic Outcomes of Post-Kidney Transplantation Superficial Urothelial Carcinoma.
    Transplant Proc. 2018;50:998-1000.
    Abstract    

    Abstract available

  25. KIDO K, Hatakeyama S, Hamano I, Yamamoto H, et al
    Partial Cystectomy of Paraganglioma of the Urinary Bladder Before Living Kidney Transplantation: Case Report.
    Transplant Proc. 2018;50:898-901.
    Abstract    

    Abstract available

  26. FUS LP, Pihowicz P, Koperski L, Marczewska JM, et al
    High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma.
    Ann Diagn Pathol. 2018;33:40-44.
    Abstract    

    Abstract available

  27. DUSKOVA K, Vesely S, DO Carmo Silva J, Cernei N, et al
    Differences in Urinary Amino Acid Patterns in Individuals with Different Types of Urological Tumor Urinary Amino Acid Patterns as Markers of Urological Tumors.
    In Vivo. 2018;32:425-429.
    Abstract    

    Abstract available

  28. FAIENA I, Cummings AL, Crosetti AM, Pantuck AJ, et al
    Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
    Drug Des Devel Ther. 2018;12:209-215.
    Abstract    

    Abstract available

  29. WANG CC, Huang CY, Jhuang YL, Chen CC, et al
    Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Histopathology. 2018;72:795-803.
    Abstract    

    Abstract available

  30. EL-GENDI S, Abu-Sheasha G
    Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.
    Pathol Oncol Res. 2018;24:309-322.
    Abstract    

    Abstract available

  31. HUANG B, Zheng J, Yao Z, Fan W, et al
    Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
    World J Urol. 2018 Sep 6. pii: 10.1007/s00345-018-2437.
    Abstract    

    Abstract available

  32. HASHEMI M, Hasanpour V, Danesh H, Bizhani F, et al
    Association between Pri-miR-34b/c rs4938723 polymorphism and bladder cancer risk.
    J Biomed Res. 2018 Sep 6. doi: 10.7555/JBR.31.20170044.
    Abstract    

    Abstract available

  33. FONTEYNE V, Rammant E, Ost P, Lievens Y, et al
    Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium.
    Clin Genitourin Cancer. 2018 Aug 11. pii: S1558-7673(18)30241.
    Abstract    

    Abstract available

  34. TABAYOYONG WB, Kamat AM, O'Donnell MA, McKiernan JM, et al
    Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Sep 3. pii: S2405-4569(18)30238.
    Abstract    

    Abstract available

  35. CHABOWSKI M, Juzwiszyn J, Malinowska K, Kostka A, et al
    The Factors Significantly affecting the Quality of Life of Patients Who undergo Radical Cystectomy due to Bladder Cancer.
    P R Health Sci J. 2018;37:1710.
    Abstract    

    Abstract available

  36. BOWA K, Mulele C, Kachimba J, Manda E, et al
    A review of bladder cancer in Sub-Saharan Africa: A different disease, with a distinct presentation, assessment, and treatment.
    Ann Afr Med. 2018;17:99-105.
    Abstract    

    Abstract available

  37. BEN FRADJ MK, Ouanes Y, Hadj-Taieb S, Sallemi A, et al
    Decreased Oleic Acid and Marine n - 3 Polyunsaturated Fatty Acids in Tunisian Patients with Urothelial Bladder Cancer.
    Nutr Cancer. 2018 Sep 5:1-8. doi: 10.1080/01635581.2018.1497668.
    Abstract    

    Abstract available

  38. FLAIG TW, Spiess PE, Agarwal N, Bangs R, et al
    NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
    J Natl Compr Canc Netw. 2018;16:1041-1053.
    Abstract    

    Abstract available

  39. PEYTON CC, Tang D, Reich RR, Azizi M, et al
    Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.
    JAMA Oncol. 2018 Aug 30. pii: 2698043. doi: 10.1001/jamaoncol.2018.3542.
    Abstract    

    Abstract available

  40. WANG F, Zu Y, Huang W, Chen H, et al
    LncRNA CALML3-AS1 promotes tumorigenesis of bladder cancer via regulating ZBTB2 by suppression of microRNA-4316.
    Biochem Biophys Res Commun. 2018 Aug 31. pii: S0006-291X(18)31844.
    Abstract    

    Abstract available

  41. LIN T, Zhou S, Gao H, Li Y, et al
    MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer.
    Technol Cancer Res Treat. 2018;17:1533033818790536.
    Abstract    

    Abstract available

  42. CAMPI R, Seisen T, Roupret M
    Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Aug 29. pii: S2405-4569(18)30229.
    Abstract    



  43. VLACHOSTERGIOS PJ, Faltas BM
    The molecular limitations of biomarker research in bladder cancer.
    World J Urol. 2018 Aug 31. pii: 10.1007/s00345-018-2462.
    Abstract    

    Abstract available

  44. LI K, Xu Y, Tan M, Xia S, et al
    A retrospective comparison of thulium laser en bloc resection of bladder tumor and plasmakinetic transurethral resection of bladder tumor in primary non-muscle invasive bladder cancer.
    Lasers Med Sci. 2018 Aug 31. pii: 10.1007/s10103-018-2604.
    Abstract    

    Abstract available

  45. ZHU N, Hou J, Wu Y, Liu J, et al
    Integrated analysis of a competing endogenous RNA network reveals key lncRNAs as potential prognostic biomarkers for human bladder cancer.
    Medicine (Baltimore). 2018;97:e11887.
    Abstract    

    Abstract available

  46. PIERCONTI F, Martini M, Straccia P, Fiorentino V, et al
    Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma.
    APMIS. 2018;126:705-709.
    Abstract    

    Abstract available

  47. SIMONE G, Tuderti G, Misuraca L, Anceschi U, et al
    Perioperative and mid-term oncologic outcomes of robotic assisted radical cystectomy with totally intracorporeal neobladder: Results of a propensity score matched comparison with open cohort from a single-centre series.
    Eur J Surg Oncol. 2018;44:1432-1438.
    Abstract    

    Abstract available

  48. WANG MS, He QB, Yang FY, Ping H, et al
    A Retrospective Study Comparing Surgical and Early Oncological Outcomes between Intracorporeal and Extracorporeal Ileal Conduit after Laparoscopic Radical Cystectomy from a Single Center.
    Chin Med J (Engl). 2018;131:784-789.
    Abstract    

    Abstract available

  49. CHEN X, Liu M, Meng F, Sun B, et al
    The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer.
    J Cell Biochem. 2018 Sep 14. doi: 10.1002/jcb.27327.
    Abstract    

    Abstract available

  50. MURAKAMI T, Yamamoto CM, Akino T, Tanaka H, et al
    Bladder cancer detection by urinary extracellular vesicle mRNA analysis.
    Oncotarget. 2018;9:32810-32821.
    Abstract    

    Abstract available

  51. YEON A, You S, Kim M, Gupta A, et al
    Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.
    Theranostics. 2018;8:4520-4534.
    Abstract    

    Abstract available

  52. PENG L, Pan P, Chen J, Yu X, et al
    A tetracycline-inducible CRISPR/Cas9 system, targeting two long non-coding RNAs, suppresses the malignant behavior of bladder cancer cells.
    Oncol Lett. 2018;16:4309-4316.
    Abstract    

    Abstract available

  53. ZHOU W, He L, Dai Y, Zhang Y, et al
    MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer.
    Exp Ther Med. 2018;16:2811-2820.
    Abstract    

    Abstract available

  54. DU E, Lu C, Sheng F, Li C, et al
    Analysis of potential genes associated with primary cilia in bladder cancer.
    Cancer Manag Res. 2018;10:3047-3056.
    Abstract    

    Abstract available

  55. YEGIN Z, Aydin O, Koc H, Buyukalpelli R, et al
    Expression profiles of proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 in bladder cancer.
    Cell Mol Biol (Noisy-le-grand). 2018;64:66-73.
    Abstract    

    Abstract available

  56. LAREYRE F, Reverso-Meinietti J, Carboni J, Gaudart A, et al
    Mycotic Aortic Aneurysm and Infected Aortic Graft After Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer.
    Vasc Endovascular Surg. 2018 Sep 13:1538574418800128.
    Abstract    

    Abstract available

  57. RAYN KN, Hale GR, Bloom JB, Gold SA, et al
    Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience.
    Diagn Interv Radiol. 2018;24:316-320.
    Abstract    

    Abstract available

  58. OTTO W
    Stage T1 bladder cancer: historic background and latest tracks for its demystification.
    Transl Androl Urol. 2018;7:760-763.
    Abstract    



  59. CULINE S, Allory Y, Pfister C
    Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization.
    Transl Androl Urol. 2018;7:757-759.
    Abstract    



  60. THIRUTHANEESWARAN N, Choudhury A
    Exploring trends in advanced bladder cancer using the NCDB: turning data into information and information into insight.
    Transl Androl Urol. 2018;7:754-756.
    Abstract    



  61. OSZCZUDLOWSKI M, Dobruch J
    Prediction of progression to muscle-invasive disease in patients with high-risk bladder cancer.
    Transl Androl Urol. 2018;7:749-751.
    Abstract    



  62. MOSCHINI M, Zamboni S, Mattei A, Martini A, et al
    Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases.
    Transl Androl Urol. 2018;7:742-744.
    Abstract    



  63. SOMANI BK
    Bladder utility symptom scale: a new patient reported outcome measure for health-related quality of life in bladder cancer.
    Transl Androl Urol. 2018;7:740-741.
    Abstract    



  64. PAN CC
    The value of molecular markers in classification and prediction of progression in non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7:736-739.
    Abstract    



  65. JOSHI SS, Handorf ER, Smaldone MC, Geynisman DM, et al
    What can the National Cancer Database tell us about disparities in advanced bladder cancer outcomes?
    Transl Androl Urol. 2018;7:732-735.
    Abstract    



  66. HAN C, Mengual L, Kang B, Lozano JJ, et al
    Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study.
    J Cancer. 2018;9:3208-3215.
    Abstract    

    Abstract available

  67. ZAVALISHINA L, Tsimafeyeu I, Povilaitite P, Raskin G, et al
    RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Virchows Arch. 2018 Sep 13. pii: 10.1007/s00428-018-2453.
    Abstract    

    Abstract available

  68. FISHER MD, Shenolikar R, Miller PJ, Fenton M, et al
    Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015.
    Clin Genitourin Cancer. 2018 Aug 11. pii: S1558-7673(18)30141.
    Abstract    

    Abstract available

  69. MANTICA G, Simonato A, Du Plessis DE, Maffezzini M, et al
    The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection.
    Minerva Urol Nefrol. 2018 Sep 10. pii: S0393-2249.18.03175.
    Abstract    

    Abstract available

  70. DAVIS RM, Kiss B, Trivedi DR, Metzner TJ, et al
    Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype.
    ACS Nano. 2018 Sep 11. doi: 10.1021/acsnano.8b03217.
    Abstract    

    Abstract available

  71. MOSSANEN M, Chu A, Smith AB, Gore JL, et al
    Inferring bladder cancer research prioritization from patient-generated online content.
    World J Urol. 2018 Sep 10. pii: 10.1007/s00345-018-2479.
    Abstract    

    Abstract available

  72. FUJIMOTO D, Mochizuki Y, Nakagiri K, Shite J, et al
    Unusual rapid progression of non-bacterial thrombotic endocarditis in a patient with bladder cancer despite undergoing intensification treatment with rivaroxaban for acute venous thromboembolism.
    Eur Heart J. 2018 Sep 9. pii: 5093360. doi: 10.1093.
    Abstract    



  73. TONG Y, Udupa JK, Wang C, Chen J, et al
    Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images.
    Adv Radiat Oncol. 2018;3:331-338.
    Abstract    

    Abstract available

  74. DO MH, To PK, Cho YS, Kwon SY, et al
    Targeting CD46 Enhances Anti-Tumoral Activity of Adenovirus Type 5 for Bladder Cancer.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  75. BAO Y, Tu X, Chang T, Qiu S, et al
    The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer: A diagnostic meta-analysis and systematic review.
    Medicine (Baltimore). 2018;97:e12227.
    Abstract    

    Abstract available

  76. WANG H, Ding W, Jiang G, Gou Y, et al
    EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
    Medicine (Baltimore). 2018;97:e12006.
    Abstract    

    Abstract available

  77. MORIZAWA Y, Miyake M, Shimada K, Hori S, et al
    Correlation Of Immune Cells And Cytokines In The Tumor Microenvironment With Elevated Neutrophil-To-Lymphocyte Ratio In Blood: An Analysis Of Muscle-Invasive Bladder Cancer.
    Cancer Invest. 2018 Sep 10:1-11. doi: 10.1080/07357907.2018.1506800.
    Abstract    

    Abstract available

  78. WANG H, Hu Z, Chen L
    Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN.
    Oncol Lett. 2018;16:4223-4228.
    Abstract    

    Abstract available

  79. WADHWA N, Mathew BB, Tandon S, Biju VG, et al
    Assessment of microsatellite instability for screening bladder cancer in high-risk population.
    J Cancer Res Ther. 2018;14:916-920.
    Abstract    

    Abstract available

  80. SVATEK RS, Tangen C, Delacroix S, Lowrance W, et al
    Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Sep 6. pii: S2405-4569(18)30234.
    Abstract    

    Abstract available

  81. SONG Y, Hu J, Chen Q, Guo J, et al
    Association between vascular endothelial growth factor rs699947 polymorphism and the risk of three major urologic neoplasms (bladder cancer, prostate cancer, and renal cell carcinoma): A meta-analysis involving 11,204 subjects.
    Gene. 2018;679:241-252.
    Abstract    

    Abstract available

  82. GHORBANMEHR N, Gharbi S, Korsching E, Tavallaei M, et al
    miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer.
    Prostate. 2018 Sep 7. doi: 10.1002/pros.23714.
    Abstract    

    Abstract available

  83. YOUSSEF K, Dembele ON, Idriss Z, Elsayegh H, et al
    [Bladder leiomyosarcoma: about 3 cases].
    Pan Afr Med J. 2018;30:19.
    Abstract    

    Abstract available

  84. HE RQ, Zhou XG, Yi QY, Deng CW, et al
    Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
    Cell Physiol Biochem. 2018;48:1355-1368.
    Abstract    

    Abstract available

  85. LI CF, Shen KH, Chien LH, Huang CH, et al
    Proteomic Identification of the Galectin-1-Involved Molecular Pathways in Urinary Bladder Urothelial Carcinoma.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  86. JALLAD S, Ghani S, Omar MA, Motiwala H, et al
    Isolated bladder schwannoma: a rare presentation.
    BMJ Case Rep. 2018;2018.
    Abstract    

    Abstract available

  87. HE L, Li S, Zheng C, Wang C, et al
    Rare symptomatic bladder leiomyoma: case report and literature review.
    J Int Med Res. 2018;46:1678-1684.
    Abstract    

    Abstract available

  88. LLORENC V, Mesquida M, Molins B, Gonzalez-Martin J, et al
    Bacillus Calmette-Guerin Infection and Cytotoxicity in the Retinal Pigment Epithelium.
    Ocul Immunol Inflamm. 2018;26:786-792.
    Abstract    

    Abstract available

  89. FANG C, He W, Xu T, Dai J, et al
    Upregulation of lncRNA DGCR5 correlates with better prognosis and inhibits bladder cancer progression via transcriptionally facilitating P21 expression.
    J Cell Physiol. 2018 Sep 21. doi: 10.1002/jcp.27356.
    Abstract    

    Abstract available

  90. MERSEBURGER AS, Apolo AB, Chowdhury S, Hahn NM, et al
    SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
    World J Urol. 2018 Sep 20. pii: 10.1007/s00345-018-2486.
    Abstract    

    Abstract available

  91. FABA OR, Tyson MD, Artibani W, Bochner BH, et al
    Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion.
    World J Urol. 2018 Sep 20. pii: 10.1007/s00345-018-2484.
    Abstract    

    Abstract available

  92. DESGRANDCHAMPS F, LeMaoult J, Goujon A, Riviere A, et al
    Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8(+) T cells.
    Oncotarget. 2018;9:33160-33169.
    Abstract    

    Abstract available

  93. CHEN C, He W, Huang J, Wang B, et al
    LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment.
    Nat Commun. 2018;9:3826.
    Abstract    

    Abstract available

  94. NICKLAS AP, Kramer MW, Serth J, Hennenlotter J, et al
    Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Adv Ther. 2018 Sep 19. pii: 10.1007/s12325-018-0789.
    Abstract    

    Abstract available

  95. LIU YR, Ortiz-Bonilla CJ, Lee YF
    Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  96. ARAGON-CHING JB, Werntz RP, Zietman AL, Steinberg GD, et al
    Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions.
    Am Soc Clin Oncol Educ Book. 2018;:307-318.
    Abstract    

    Abstract available

  97. ZHAO H, Bo Q, Wang W, Wang R, et al
    CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer.
    J Cell Biochem. 2018 Sep 19. doi: 10.1002/jcb.27494.
    Abstract    

    Abstract available

  98. WANG FH, Ma XJ, Xu D, Luo J, et al
    UPK1B promotes the invasion and metastasis of bladder cancer via regulating the Wnt/beta-catenin pathway.
    Eur Rev Med Pharmacol Sci. 2018;22:5471-5480.
    Abstract    

    Abstract available

  99. POCH M, Hall M, Joerger A, Kodumudi K, et al
    Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.
    Oncoimmunology. 2018;7:e1476816.
    Abstract    

    Abstract available

  100. KOGA F, Takemura K, Fukushima H
    Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  101. VAN DER POL CB, Chung A, Lim C, Gandhi N, et al
    Update on multiparametric MRI of urinary bladder cancer.
    J Magn Reson Imaging. 2018 Sep 17. doi: 10.1002/jmri.26294.
    Abstract    

    Abstract available

  102. TAO T, Su Q, Xu S, Deng J, et al
    Downregulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
    J Cell Physiol. 2018 Sep 17. doi: 10.1002/jcp.27129.
    Abstract    

    Abstract available

  103. PRINCE T, Ackerman A, Cavanaugh A, Schreiter B, et al
    Dual targeting of HSP70 does not induce the heat shock response and synergistically reduces cell viability in muscle invasive bladder cancer.
    Oncotarget. 2018;9:32702-32717.
    Abstract    

    Abstract available

  104. WANG HF, Wu JH, Gai JW, Yang SQ, et al
    MAN1B1 is associated with poor prognosis and modulates proliferation and apoptosis in bladder cancer.
    Gene. 2018;679:314-319.
    Abstract    

    Abstract available

  105. COMPERAT E, Babjuk M, Algaba F, Amin M, et al
    SIU-ICUD on bladder cancer: pathology.
    World J Urol. 2018 Sep 14. pii: 10.1007/s00345-018-2466.
    Abstract    

    Abstract available

  106. MITIN T, Choudhury A
    The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer.
    World J Urol. 2018 Sep 14. pii: 10.1007/s00345-018-2480.
    Abstract    

    Abstract available

  107. NUTT M, Scaief S, Dynda D, Alanee S, et al
    Ileus and small bowel obstruction after radical cystectomy for bladder cancer: Analysis from the Nationwide Inpatient Sample.
    Surg Oncol. 2018;27:341-345.
    Abstract    

    Abstract available

  108. SAFINI F, Jouhadi H, Marnissi F, Bouchbika Z, et al
    [Small cell neuroendocrine carcinoma of the bladder: Report of five cases and a review of the literature].
    Cancer Radiother. 2018;22:417-422.
    Abstract    

    Abstract available

  109. CHEN X, Jia C, Jia C, Jin X, et al
    MicroRNA-374a Inhibits Aggressive Tumor Biological Behavior in Bladder Carcinoma by Suppressing Wnt/beta-Catenin Signaling.
    Cell Physiol Biochem. 2018;48:815-826.
    Abstract    

    Abstract available

  110. REIS H, Krafft U, Niedworok C, Modos O, et al
    Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.
    Dis Markers. 2018;2018:7308168.
    Abstract    

    Abstract available

  111. YANG J, Ren Y, Lou ZG, Wan X, et al
    Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3.
    Acta Pharm. 2018;68:211-222.
    Abstract    

    Abstract available

  112. RADES D, Dziggel L, Manig L, Janssen S, et al
    Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder.
    In Vivo. 2018;32:633-636.
    Abstract    

    Abstract available

  113. AGGARWAL A, Singh V, Pandey S, Sinha RJ, et al
    Embryonal rhabdomyosarcoma of urinary bladder in an adult patient: an unusual manifestation.
    BMJ Case Rep. 2018;2018.
    Abstract    

    Abstract available

  114. ARAI T, Fuse M, Goto Y, Kaga K, et al
    Molecular pathogenesis of interstitial cystitis based on microRNA expression signature: miR-320 family-regulated molecular pathways and targets.
    J Hum Genet. 2018;63:543-554.
    Abstract    

    Abstract available

  115. CHEN XF, Yeong J, Chang KTE, Lim AST, et al
    TFE3-Expressing Epithelioid Rich Perivascular Epithelioid Cell Neoplasm (PEComa) of the Bladder with Unusual Benign Course.
    Ann Clin Lab Sci. 2018;48:110-115.
    Abstract    

    Abstract available

  116. SUREKA B, Jain V, Jain S, Rastogi A, et al
    Cystitis Cystica Glandularis: Radiological Imitator of Urothelial Carcinoma.
    Iran J Kidney Dis. 2018;12:10.
    Abstract    



  117. LEE C, Kim B, Song B, Park JH, et al
    Clinicopathologic Features of Benign Neurogenic Tumor of Urinary Bladder.
    Int J Surg Pathol. 2018;26:221-228.
    Abstract    

    Abstract available

  118. ZACHOVAL R, Dukatova K, Svabik K
    Vaginal ultrasound for imaging of a urinary bladder mass and treatment of a large leiomyoma of the urinary bladder in pregnancy.
    Int Urogynecol J. 2018;29:601-602.
    Abstract    



  119. TSAI TH, Wang YM, Chang WS, Tsai CW, et al
    Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer.
    Anticancer Res. 2018;38:5159-5164.
    Abstract    

    Abstract available

  120. LEA MA, Kim H, desBORDES C
    Effects of Biguanides on Growth and Glycolysis of Bladder and Colon Cancer Cells.
    Anticancer Res. 2018;38:5003-5011.
    Abstract    

    Abstract available


  121. Editor's Note: Curcumin Potentiates the Antitumor Effects of Bacillus Calmette-Guerin against Bladder Cancer through the Downregulation of NF-kappaB and Upregulation of TRAIL Receptors.
    Cancer Res. 2018;78:5182.
    Abstract    



  122. SEILER R, Gibb EA, Wang NQ, Oo HZ, et al
    Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1106.
    Abstract    

    Abstract available

  123. SORIA F, D'Andrea D, Pohar K, Shariat SF, et al
    Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?
    Curr Opin Urol. 2018 Aug 27. doi: 10.1097/MOU.0000000000000545.
    Abstract    

    Abstract available

  124. MANNAS MP, Lee T, Nykopp TK, Costa JBD, et al
    A risk-stratified approach to the management of high-grade T1 bladder cancer.
    Curr Opin Urol. 2018 Aug 24. doi: 10.1097/MOU.0000000000000548.
    Abstract    

    Abstract available

  125. BRUCHBACHER A, Soria F, Hassler M, Shariat SF, et al
    Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice?
    Curr Opin Urol. 2018 Sep 3. doi: 10.1097/MOU.0000000000000546.
    Abstract    

    Abstract available

  126. LINARES-ESPINOS E, Sanchez-Salas R
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 22. pii: S0302-2838(18)30562.
    Abstract    



  127. MOSTAFID H, Palou J, Burger M, Babjuk M, et al
    T1 High-grade Bladder Cancer: The Search for the Optimal Management Continues.
    Eur Urol. 2018 Aug 30. pii: S0302-2838(18)30601.
    Abstract    



  128. TAN TZ, Rouanne M, Tan KT, Huang RY, et al
    Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Eur Urol. 2018 Sep 10. pii: S0302-2838(18)30619.
    Abstract    

    Abstract available

  129. GARG H, Nayak B, Singh P
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30648.
    Abstract    



  130. DYRSKJOT L
    Molecular Subtypes of Bladder Cancer: Academic Exercise or Clinical Relevance?
    Eur Urol. 2018 Sep 17. pii: S0302-2838(18)30656.
    Abstract    



  131. NECCHI A, Anichini A, Sonpavde G
    Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum.
    Eur Urol. 2018;73:153-155.
    Abstract    



  132. WILSON SS, Crawford ED
    Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.
    Eur Urol. 2018;73:233-235.
    Abstract    



  133. HERMANS TJN, Voskuilen CS, Deelen M, Mertens LS, et al
    Superior Efficacy of Neoadjuvant Chemotherapy and Radical Cystectomy in cT3-4aN0M0 compared to cT2N0M0 Bladder Cancer.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31833.
    Abstract    



  134. PIAO XM, Jeong P, Kim YH, Byun YJ, et al
    Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31849.
    Abstract    

    Abstract available

  135. WANG Z, Li C, Jiang M, Chen J, et al
    Filamin A (FLNA) regulates autophagy of bladder carcinoma cell and affects its proliferation, invasion and metastasis.
    Int Urol Nephrol. 2018;50:263-273.
    Abstract    

    Abstract available

  136. MARUF M, Sidana A, Purnell S, Jain AL, et al
    Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database.
    Int Urol Nephrol. 2018;50:257-262.
    Abstract    

    Abstract available

  137. MOSSANEN M, Caldwell J, Sonpavde G, Lehmann LS, et al
    Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?
    J Clin Oncol. 2018 Sep 13:JCO1800577. doi: 10.1200/JCO.18.00577.
    Abstract    



  138. CHANG SS
    Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2018;200:696-697.
    Abstract    



  139. LIU CP, Zhang JH, Zheng SC, Liu J, et al
    A novel clinical multidimensional transcriptome signature predicts prognosis in bladder cancer.
    Oncol Rep. 2018;40:2826-2835.
    Abstract    

    Abstract available

  140. LEBRUN L, Milowich D, Le Mercier M, Allard J, et al
    UCA1 overexpression is associated with less aggressive subtypes of bladder cancer.
    Oncol Rep. 2018;40:2497-2506.
    Abstract    

    Abstract available

  141. PIGNOT G, Houede N, Roumiguie M, Audenet F, et al
    [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Prog Urol. 2018 Sep 8. pii: S1166-7087(18)30181.
    Abstract    

    Abstract available

  142. VETTERLEIN MW, Gild P, Marks P, Roschinski J, et al
    Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation.
    Urol Int. 2018 Sep 20:1-8. doi: 10.1159/000493369.
    Abstract    

    Abstract available

  143. KRAJEWSKI W, Matuszewski M, Poletajew S, Grzegrzolka J, et al
    Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients.
    Urol Int. 2018 Sep 18:1-8. doi: 10.1159/000492722.
    Abstract    

    Abstract available

  144. KHANNA A, Yerram N, Zhu H, Kim S, et al
    "Utilization of BCG for Non-Muscle Invasive Bladder Cancer in an Era of BCG Supply Shortages".
    Urology. 2018 Sep 13. pii: S0090-4295(18)30951.
    Abstract    

    Abstract available

  145. WIJBURG CJ, Michels CTJ, Oddens JR, Grutters JPC, et al
    Robot assisted radical cystectomy versus open radical cystectomy in bladder cancer (RACE): study protocol of a non-randomized comparative effectiveness study.
    BMC Cancer. 2018;18:861.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;